leadf
logo-loader
viewBotanix Pharmaceuticals Ltd

Botanix Pharmaceuticals raises $40mln to push its CBD-based skin disease treatments through the pipeline

Botanix Pharmaceuticals Limited (ASX:BOT) CEO Matt Callahan tells Proactive Investors the clinical-stage pharma company has raised $40 million.

Callahan says the cash will allow the Sydney, Australia, and Philadelphia, Pennsylvania-based company to accelerate its preclinical and clinical work in bringing its CBD-based skin disease treatments to phase 3. Additionally, these funds will allow the company to bring into the clinic its first application of CBD as a stand-alone antimicrobial. 

Quick facts: Botanix Pharmaceuticals Ltd

Price: 0.075 AUD

ASX:BOT
Market: ASX
Market Cap: $72.95 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Lithium Australia 'taking Elon Musk's vision to disrupt the supply chain one...

Lithium Australia NL (ASX:LIT) managing director Adrian Griffin gives his response to comments made by Elon Musk at this week's Tesla Battery Day. With Musk's ambition to minimise the steps from mining to battery production, Griffin says they've developed the technology needed to take that one...

1 day, 12 hours ago

2 min read